Cytotoxic T lymphocyte-associated protein 4 (CTLA4), also named CD152, is a membrane protein receptor acting as a negative regulator of T cell responsive when bound to its ligands on the surface of antigen-presenting cells, including CD80 and CD86. The dysfunction and overactivation of CTLA4 has been proved to lead to immune dysfunction syndrome and tumor immunological escape, its monoclonal antibody, Ipilimumab, is the first approved immune checkpoint blockade therapy and has been proved to be a potential therapeutically strategy for cancer patient.